Arcus Development Group Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Arcus Development Group in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Arcus Development Group vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Arcus Development Group | - | - | - | - | - | - | - |
| Trailbreaker Resources Ltd. | 8.110% | 8.696% | -1.961% | 35.135% | 55.039% | 2.564% | 19.760% |
| Cannabix Techs Inc. | -1.230% | 2.564% | -4.192% | -7.514% | -10.615% | 78.771% | -48.800% |
| Mundoro Capital Inc. | 17.780% | -7.826% | 3.922% | 81.197% | 59.398% | 103.846% | 35.032% |
News
Arcus Biosciences Q2 Earnings Call Highlights
Key Points
- Interested in Arcus Biosciences, Inc.? Here are five stocks we like better.
- Casdatifan is Arcus’ top priority: The company is expanding the HIF-2 alpha inhibitor’s development across
Summit Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Summit Therapeutics PLC? Here are five stocks we like better.
- Updated HARMONi trial data showed a median follow-up improvement and an overall survival hazard ratio of
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
Juan C. Jaen, the president of Arcus Biosciences, Inc. (NYSE:RCUS), reported a sale of 68,569 shares on July 9, 2026 and July 10, 2026, according to an SEC Form 4 filing.
Arcus Biosciences is a
